Grace Therapeutics
Update in progressGRCE (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Grace Therapeutics, Inc. develops and commercializes pharmaceutical products for rare and orphan diseases in Canada. Its lead candidate, GTX-104, is an intravenous therapy for subarachnoid hemorrhage. Other programs include GTX-102, an oral betamethasone spray for Ataxia‑Telangiectasia, and GTX-101, a topical bioadhesive film for postherpetic neuralgia pain. Formerly Acasti Pharma, it renamed in October 2024. Founded 2002, it is based in Princeton, New Jersey.
Company score
- Sentiment
- 0.44
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.37
- Governance
- 0.17
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.14
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.29
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!